WINCHESTER, Mass.--(BUSINESS WIRE)--Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that successful results of an acute in vivo study of its TMVI system were disclosed by Dr. Joseph Bavaria during the “Mitral Valve Therapies Prior to and in Human Investigation” program at the “Transcatheter Cardiovascular Therapeutics (TCT) 2009” annual scientific meeting on Friday.
